International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

International System for Human Cytogenetic Nomenclature

National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619

Myelodysplastic syndromes: a scoring system with prognostic significance

Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406

The 5q− anomaly

BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia

Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes

Li, B., Liu, J., Jia, Y., Wang, J., Xu, Z., Qin, T., Shi, Z., Song, Z., Peng, S., Huang, H., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22510 · Cited by 66

Myelodysplastic syndrome: a search for minimal diagnostic criteria

Ramos, F., Fernández-Ferrero, S., Suárez, D., Barbón, M., Rodrı́guez, J. A., Gil, S., Megido, M., Ciudad, J., López, N., del Cañizo, C., et al. (1999) · Leukemia Research · doi:10.1016/s0145-2126(98)00166-0 · Cited by 66

Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients

BERNASCONI, P. P., Cavigliano, P. M., Boni, M., Calatroni, S., Klersy, C., Giardini, I., Rocca, B., Crosetto, N., Caresana, M., Lazzarino, M., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403108 · Cited by 66

The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment

Bennett, J. M., & Komrokji, R. S. (2005) · Hematology · doi:10.1080/10245330512331390311 · Cited by 66

Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia

Lezon-Geyda, K., Najfeld, V., & Johnson, E. (2001) · Leukemia · doi:10.1038/sj.leu.2402108 · Cited by 66

Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD

Claessens, Y.-É., Park, S., Dubart‐Kupperschmitt, A., Mariot, V., Garrido, C., Chrétien, S., Dreyfus, F., Lacombe, C., Mayeux, P., & Fontenay, M. (2005) · Blood · doi:10.1182/blood-2004-08-3166 · Cited by 66

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Bravo, G. M., Takahashi, K., Patel, K. P., Wang, F., Xingzhi, S., Nogueras, G. M., Huang, X., Piérola, A. A., Jabbour, E. J., Colla, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23882 · Cited by 67

Inflammatory Arthritis in Patients With Myelodysplastic Syndromes

MEKINIAN, A., Braun, T., Decaux, O., Falgarone, G., Toussirot, É., Raffray, L., Omouri, M., Gombert, B., de Wazières, B., Buchdaul, A.-L., et al. (2013) · Medicine · doi:10.1097/md.0000000000000011 · Cited by 65

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission

Martino, R., Valcárcel, D., Brunet, S., Sureda, A. M., & Sierra, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705879 · Cited by 65

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Raza, A., Galili, N., Smith, S. E., Godwin, J. E., Lancet, J. E., Melchert, M., Jones, M., Keck, J., Meng, L., Brown, G. L., et al. (2009) · Blood · doi:10.1182/blood-2009-01-176032 · Cited by 65

Myelodysplastic syndromes: biology and treatment

Jädersten, M., & Hellström‐Lindberg, E. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02052.x · Cited by 65

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis

Kröger, N. M., Zabelina, T., van Biezen, A., Brand, R., Niederwieser, D. W., Martino, R., Lim, Z. Y., Onida, F., Schmid, C., Garderet, L., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031229 · Cited by 65

Decitabine in the treatment of myelodysplastic syndromes

Santos, F. P., Kantarjian, H. M., Garcia‐Manero, G., Issa, J. J., & Ravandi, F. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.164 · Cited by 66

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

Zeidan, A. M., Ali, N. E. A., Barnard, J., Padron, E., Lancet, J. E., Sekeres, M. A., Steensma, D. P., Dezern, A. E., Roboz, G. J., Jabbour, E. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.33 · Cited by 65

Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

Tefferi, A., Dingli, D., Li, C., & Dewald, G. W. (2005) · Cancer · doi:10.1002/cncr.21358 · Cited by 65

The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology

Paulsson, K. M., Säll, T., Fioretos, T., Mitelman, F., & Johansson, B. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00486-1 · Cited by 65

Acute myeloid leukemia in the elderly: biology and therapeutic strategies

Pinto, A., Zagonel, V., & Ferrara, F. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00122-0 · Cited by 65

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Takahashi, K., Jabbour, E. J., Wang, X., Luthra, R., Bueso‐Ramos, C. E., Patel, K. P., Pierce, S. A., Yang, H., Wei, Y., Daver, N. G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.165 · Cited by 64

FISH and SNP-A karyotyping in myelodysplastic syndromes: Improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q)

Makishima, H., Rataul, M. S., Gondek, L. P., Huh, J., Cook, J. R., Theil, K. S., Sekeres, M. A., Kuczkowski, E., O’Keefe, C. L., & Maciejewski, J. P. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.08.023 · Cited by 64

Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan

Ishii, H., Seymour, J. F., Tazawa, R., Inoue, Y., Uchida, N., Nishida, A., Kogure, Y., Saraya, T., Tomii, K., Takada, T., et al. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-37 · Cited by 64

Transplantation in Remission Improves the Disease-Free Survival of Patients with Advanced Myelodysplastic Syndromes Treated with Myeloablative T Cell-Depleted Stem Cell Transplants from HLA-Identical Siblings

Castro-Malaspina, H. R., Jabubowski, A. A., Papadopoulos, E. B., Boulad, F., Young, J. W., Kernan, N. A., Perales, M., Small, T. N., Hsu, K. C., Chiu, M., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.02.006 · Cited by 64

GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia

Guezguez, B., Almakadi, M., Benoit, Y. D., Shapovalova, Z., Rahmig, S., Fiebig‐Comyn, A., Casado, F. L., Tanasijevic, B., Bresolin, S., Masetti, R., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.012 · Cited by 67

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Heidenreich, S., Ziagkos, D., de Wreede, L. C., van Biezen, A., Finke, J., Platzbecker, U., Niederwieser, D. W., Einsele, H., Bethge, W. A., Schleuning, M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.027 · Cited by 64

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an MDS ‐ CAN analysis

Leitch, H. A., Parmar, A., Wells, R. A., Chodirker, L., Zhu, N. Y., Nevill, T. J., Yee, K. W. L., Leber, B. F., Keating, M., Sabloff, M., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14825 · Cited by 65

Dysplastic versus proliferative CMML – a retrospective analysis of 91 patients from a single institution

Nösslinger, T., Reisner, R., Grüner, H., Tüchler, H., Nowotny, H., Pittermann, E., & Pfeilstöcker, M. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00014-5 · Cited by 64

Two types of acquired idiopathic sideroblastic anaemia (AISA): a time‐tested distinction

Germing, U., Gattermann, N., Aivado, M. A., Hildebrandt, B., & Aul, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01940.x · Cited by 64

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes

Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63

Preleukemia: one name, many meanings

Koeffler, H. P., & Leong, G. X. Y. (2016) · Leukemia · doi:10.1038/leu.2016.364 · Cited by 67

Superiority of prolonged low‐dose azanucleoside administration?

Rüter, B. H., Wijermans, P., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.21796 · Cited by 63

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

Nilsson‐Ehle, H., Birgegård, G., Samuelsson, J., Antunović, P., Astermark, J., Garelius, H. G., Engström, L. M., Kjeldsen, L., Nilsson, L., Olsson, A., et al. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01654.x · Cited by 63

Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation

Gupta, R., Soupir, C. P., Johari, V. P., & Hasserjian, R. P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06776.x · Cited by 63

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

On behalf of the IRON-2 Study Group, Remacha, A. F., Arrizabalaga, B., Villegas, A., Durán, M. S., Hermosín, L., de Paz, R., García, M., Díez‐Campelo, M., & Sanz, G. F. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2274-y · Cited by 63

Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome

McGowan, K. A., Pang, W. W., Bhardwaj, R., Perez, M. G., Pluvinage, J. V., Glader, B. E., Malek, R. A., Mendrysa, S. M., Weissman, I. L., Park, C. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-11-318584 · Cited by 66

The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman‐Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies

Maserati, E., Pressato, B., Valli, R., Minelli, A., Sainati, L., Patitucci, F., Marletta, C., Mastronuzzi, A., Poli, F., Curto, F. L., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07611.x · Cited by 63

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

Cashen, A. F., Juckett, M. B., Jumonville, A. J., Litzow, M. R., Flynn, P. J., Eckardt, J. R., LaPlant, B. R., Laumann, K. M., Erlichman, C., & DiPersio, J. F. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1240-1 · Cited by 63

Hematologic Abnormalities and Outcome of 16 Cats with Myelodysplastic Syndromes

Hisasue, M., Okayama, H., Okayama, T., Suzuki, T., Mizuno, T., Fujino, Y., Naganobu, K., Hasegawa, A., WATARI, T., Matsuki, N., et al. (2001) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2001.tb01577.x · Cited by 63

Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.

Remacha, A. F., Arrizabalaga, B., Villegas, A., Manteiga, R., Calvo, T., Julià, A., Fuertes, I. F., González, F. A., Font, L., Juncà, J., et al. (1999) · PubMed · Cited by 63

The Mayo Clinic experience

Hassan, A., & Wijdicks, E. F. M. (2013) · Practical Neurology · doi:10.1136/practneurol-2013-000777 · Cited by 62

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

Chien, K. S., Kim, K., Nogueras‐González, G. M., Borthakur, G. M., Naqvi, K., Daver, N. G., Bravo, G. M., Cortes, J. E., Dinardo, C. D., Jabbour, E. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17689 · Cited by 62

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia ( AML ) and myelodysplastic syndrome ( MDS )

Dinardo, C. D., Garcia‐Manero, G., Pierce, S. A., Nazha, A., Bueso-Ramos, C., Jabbour, E. J., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24252 · Cited by 70

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research

Potter, V. T., Iacobelli, S., van Biezen, A., Maertens, J., Bourhis, J.-H., Passweg, J. R., Yakoub‐Agha, I., Tabrizi, R., Bay, J., Chevallier, P., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.05.026 · Cited by 62

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease

Tobiasson, M., Abdulkadir, H., Lennartsson, A., Katayama, S., Marabita, F., Paepe, A. D., Karimi, M., Krjutškov, K., Einarsdóttir, E., Grövdal, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15807 · Cited by 64

Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases

Lindberg, E. H., Schmidt‐Mende, J., Forsblom, A., Christensson, B., Fadeel, B., & Zhivotovsky, B. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02581.x · Cited by 62

Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan

Shimamoto, T., Tohyama, K., Okamoto, T., Uchiyama, T., Mori, H., Tomonaga, M., Asano, Y., Niho, Y., Teramura, M., Mizoguchi, H., et al. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00008-0 · Cited by 62

Interleukin-1 (IL-1) and the inflammasome in cancer

Prêtre, V., Papadopoulos, D., Regard, J. B., Pelletier, M. R., & Woo, J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155850 · Cited by 66

Quality of life and physicians' perception in myelodysplastic syndromes.

En, O., Finelli, C., Santini, V., Poloni, A., Liso, V., Cilloni, D., Impera, S. S., Terenzi, A., Levis, A., Cortelezzi, A., et al. (2012) · Europe PMC (PubMed Central) · Cited by 61

Myelodysplastic Syndromes

Germing, U., Kobbe, G., Haas, R. R., & Gattermann, N. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0783 · Cited by 67

Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group

Heilig, C. E., Löffler, H., Mahlknecht, U., Janssen, J. W. G., Ho, A. D., Jauch, A. S., & Krämer, A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00905.x · Cited by 61

Circulating Adiponectin and Leptin in Relation to Myelodysplastic Syndrome: A Case-Control Study

Dalamaga, Μ., Nikolaidou, A., Καρμανιώλας, Κ., Hsi, A., Chamberland, J. P., Dionyssiou‐Asteriou, A., & Mantzoros, C. S. (2007) · Oncology · doi:10.1159/000120995 · Cited by 61

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation

Armand, P. A., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Ritz, J., Alyea, E. P., Antin, J. H., & Soiffer, R. J. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.07.016 · Cited by 61

Additional Prognostic Value of Bone Marrow Histology in Patients Subclassified According to the International Prognostic Scoring System for Myelodysplastic Syndromes

Verburgh, E. R., Achten, R., Maes, B., Hagemeijer, A., Boogaerts, M. A., Wolf‐Peeters, C. D., & Verhoef, G. E. G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.182 · Cited by 61

Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes

Tiu, R. V., Gondek, L. P., O'Keefe, C., & Maciejewski, J. P. (2007) · Leukemia · doi:10.1038/sj.leu.2404757 · Cited by 60

Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes

Wimazal, F., Germing, U., Kundi, M., Noesslinger, T., Blum, S., Geißler, P., Baumgärtner, C., Pfeilstöecker, M., Valent, P., & Sperr, W. R. (2010) · Cancer · doi:10.1002/cncr.25036 · Cited by 61

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Wang, E. S., Lyons, R. M., Larson, R. A., Gandhi, S. G., Liu, D., Matei, C., Scott, B. L., Hu, K., & Yang, A. S. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-71 · Cited by 63

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia

Liu, H. D., Ahn, K. W., Hu, Z., Hamadani, M., Nishihori, T., Wirk, B. M., Beitinjaneh, A., Rizzieri, D. A., Grunwald, M. R., Sabloff, M., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.078 · Cited by 61

Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells

Ouseph, M. M., Hasserjian, R. P., Cin, P. D., Lovitch, S. B., Steensma, D. P., Nardi, V., & Weinberg, O. K. (2020) · Haematologica · doi:10.3324/haematol.2019.240689 · Cited by 61

Assessment of Prognosis in Patients With Community-Acquired Pneumonia Who Require Mechanical Ventilation

Pascual, F. E., Matthay, M. A., Bacchetti, P., & Wachter, R. M. (2000) · CHEST Journal · doi:10.1378/chest.117.2.503 · Cited by 61

Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia

Follo, M. Y., Finelli, C., Clissa, C., Mongiorgi, S., Bosi, C., Martinelli, G., Baccarani, M., Manzoli, L., Martelli, A. M., & Cocco, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3748 · Cited by 60

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

Zeidan, A. M., Kharfan‐Dabaja, M. A., & Komrokji, R. S. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000016 · Cited by 60

Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes

Kolquist, K. A., Schultz, R. A., Furrow, A., Brown, T. C., Han, J., Campbell, L. J., Wall, M., Slovak, M. L., Shaffer, L. G., & Ballif, B. C. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.10.004 · Cited by 60

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

Boehrer, S., Adès, L., Tajeddine, N., Hofmann, W.-K., Kriener, S., Bug, G., Ottmann, O. G., Ruthardt, M., Galluzzi, L., Fouassier, C., et al. (2009) · Oncogene · doi:10.1038/onc.2009.69 · Cited by 62

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)

Valent, P., Orazi, A., Büsche, G., Schmitt-Graeff, A. H., George, T. I., Sotlar, K., Streubel, B., Beham‐Schmid, C., Cerny‐Reiterer, S., Krieger, O., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.185 · Cited by 60

Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

Grövdal, M., Karimi, M., Khan, R., Aggerholm, A., Antunović, P., Astermark, J., Bernell, P., Engström, L.-M., Kjeldsen, L., Linder, O., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08235.x · Cited by 60

Myelodysplastic Syndromes Arising in Patients With Germline TP53 Mutation and Li-Fraumeni Syndrome

Talwalkar, S. S., Yin, C. C., Naeem, R. C., Hicks, J. M., Strong, L. C., & Abruzzo, L. V. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0015-oa.1 · Cited by 60

Therapy related‐chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML

Patnaik, M. M., Vallapureddy, R. R., Yalniz, F., Hanson, C. A., Ketterling, R. P., Lasho, T. L., Finke, C. M., Al‐Kali, A., Gangat, N., & Tefferi, A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24939 · Cited by 60

Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis

Flynn, C. M., Hirsch, B. A., DeFor, T. E., Barker, J. N., Miller, J. S., Wagner, J. E., Blazar, B. R., Burns, L. J., MacMillan, M. L., Arora, M., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.20989 · Cited by 60

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives

Musto, P. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.08.007 · Cited by 60

Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression

Hou, H., Kuo, Y., Tang, J., Chou, W., Yao, M., Lai, Y.-J., Lin, C., Chen, C., Liu, C., Tseng, M., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23611 · Cited by 59

Cardiac iron overload in transfusion‐dependent patients with myelodysplastic syndromes

Roy, N. B. A., Myerson, S. G., Schuh, A., Bignell, P. A., Patel, R., Wainscoat, J. S., McGowan, S. J., Marchi, E., Atoyebi, W., Littlewood, T. J., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08749.x · Cited by 59

Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway

Pavlaki, K. I., Pontikoglou, C. G., Demetriadou, A., Batsali, A. K., Damianaki, A., Simantirakis, E., Kontakis, M., Galanopoulos, A. G., Kotsianidis, Ι., Kastrinaki, M.-C., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0283 · Cited by 61

Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients

Dalamaga, Μ., Καρμανιώλας, Κ., Matekovits, A., Migdalis, I. N., & Papadavid, E. (2007) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2007.02520.x · Cited by 59

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Yeh, P. S.-H., Dickinson, M. J., Ftouni, S., Hunter, T., Sinha, D., Wong, S. Q., Agarwal, R., Vedururu, R., Doig, K., Fong, C. Y., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740308 · Cited by 59

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 69

New data shed light on Y‐loss‐related pathogenesis in myelodysplastic syndromes

Ganster, C., Kämpfe, D., Jung, K., Braulke, F., Shirneshan, K., Machherndl‐Spandl, S., Suessner, S., Bramlage, C. P., Legler, T. J., Koziolek, M. J., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22282 · Cited by 57

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Nand, S., Godwin, J. E., Smith, S. E., Barton, K., Michaelis, L. C., Alkan, S., Veerappan, R., Rychlik, K. L., Germano, E., & Stiff, P. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802451254 · Cited by 58

Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

Chan, G. W., DiVenuti, G., & Miller, K. B. (2002) · American Journal of Hematology · doi:10.1002/ajh.10209 · Cited by 58

Genomic landscape of CD34 + hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers

Xu, L. P., Gu, Z., Li, Y., Zhang, J.-L., Chang, C., Pan, C., Shi, J., Shen, Y., Chen, B., Wang, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407688111 · Cited by 58

Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results from an Internet-Based Survey

Sekeres, M. A., Maciejewski, J. P., List, A. F., Steensma, D. P., Artz, A. S., Swern, A. S., Scribner, P., Huber, J., & Stone, R. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0199 · Cited by 60

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

Heuser, M., Gabdoulline, R. R., Löffeld, P., Dobbernack, V., Kreimeyer, H., Pankratz, M., Flintrop, M., Liebich, A., Klesse, S., Panagiota, V., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3027-5 · Cited by 58

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

Abaza, Y., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Borthakur, G. M., Ferrajoli, A., Estrov, Z. E., Wierda, W. G., Piérola, A. A., Chong, T. H., et al. (2017) · Cancer · doi:10.1002/cncr.30949 · Cited by 59

Mutations and prognosis in myelodysplastic syndromes: karyotype‐adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model

Gangat, N., Mudireddy, M., Lasho, T. L., Finke, C. M., Nicolosi, M., Szuber, N., Patnaik, M. M., Pardanani, A. D., Hanson, C. A., Ketterling, R. P., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25064 · Cited by 59

Azacitidine in the ‘real‐world’: an evaluation of 1101 higher‐risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada

Mozessohn, L., Cheung, M. C., Fallahpour, S., Gill, T., Maloul, A., Zhang, L., Lau, O., & Buckstein, R. J. (2018) · British Journal of Haematology · doi:10.1111/bjh.15273 · Cited by 57

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

Hoeks, M. P. A., Yu, G., Langemeijer, S. M. C., Crouch, S., de Swart, L., Fenaux, P., Symeonidis, A. S., Čermák, J., Hellström‐Lindberg, E., Sanz, G. F., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.212332 · Cited by 58

Myelodysplasia with fibrosis: a distinct entity?

Steensma, D. P., Hanson, C. A., Letendre, L., & Tefferi, A. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00055-8 · Cited by 58

Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes

Olney, H. J., & Beau, M. M. L. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.10.023 · Cited by 57

NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors

Benito, A. I., Bryant, E. M., Loken, M. R., Sale, G. E., Nash, R. A., Gass, M. J., & Deeg, H. J. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00221-7 · Cited by 58

Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications

Lorand-Metze, I. G. H., Pinheiro, M. D. O., Ribeiro, E., Paula, E. V. D., & Metze, K. (2004) · Leukemia Research · doi:10.1016/j.leukres.2003.11.001 · Cited by 58

The utility of next‐generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes

Duncavage, E. J., & Tandon, B. (2015) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12361 · Cited by 58

Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party

Robin, M., Ruggeri, A., Labopin, M., Niederwieser, D. W., Tabrizi, R., Sanz, G. F., Bourhis, J.-H., van Biezen, A., Koenecke, C., Blaise, D., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.675 · Cited by 57

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform

Valent, P., Krieger, O., Stauder, R., Wimazal, F., Nösslinger, T., Sperr, W. R., Sill, H., Bettelheim, P., & Pfeilstöcker, M. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01915.x · Cited by 58

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

Komrokji, R. S., Raza, A., Lancet, J. E., Ren, C., Taft, D. R., Maniar, M. L., Wilhelm, F. E., & List, A. F. (2013) · British Journal of Haematology · doi:10.1111/bjh.12436 · Cited by 57

Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows

Buckstein, R. J., Jang, K., Friedlich, J. D., Zhang, L., Reis, M. D., Chesney, A. E., & Wells, R. A. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.02.010 · Cited by 57

Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification

Matsuda, A., Germing, U., Jinnai, I., Iwanaga, M., Misumi, M., Kuendgen, A., Strupp, C., Miyazaki, Y., Tsushima, H., Sakai, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404571 · Cited by 57

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy

Gill, H., Leung, A. Y. H., & Kwong, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040440 · Cited by 58

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

Beličková, M., Veselá, J., Jonasova, A. T., Pejsova, B., Votavová, H., Merkerová, M. D., Zemanová, Z., Březinová, J., Mikulenková, D., Lauermannová, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9200 · Cited by 56

Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome

Lee, S. J., Park, J. K., Lee, E. Y., Joo, S. H., Jung, K. C., Lee, E. B., Song, Y. W., & Yoon, S. (2016) · Medicine · doi:10.1097/md.0000000000003091 · Cited by 57

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

de Montalembert, M., Ribeil, J., Brousse, V. A. M., Guerci‐Bresler, A., Stamatoullas, A., Vannier, J., Dumesnil, C., Lahary, A., Touati, M., Bouabdallah, K. K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172147 · Cited by 57

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study

Voso, M. T., Leone, G. G. M., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., Criscuolo, M., Masciulli, A., Cerqui, E., Molteni, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx154 · Cited by 57

Epigenetics in myelodysplastic syndromes

Heuser, M., Yun, H., & Thol, F. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.009 · Cited by 61

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

Hofmann, W.-K., Heil, G., Zander, C., Wiebe, S., Ottmann, O. G., Bergmann, L., Hoeffken, K., Fischer, J. T., Knuth, A. K., Kolbe, K., et al. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0889-0 · Cited by 57

Risk factors and their relationship to prognosis in myelodysplastic syndromes

Greenberg, P. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00040-x · Cited by 19

Clinical Prognostic Factors for Survival and Risk of Progression to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndromes With < 10% Marrow Blasts and Non-Unfavorable Cytogenetic Categories

Falantes, J. F., Calderón, C., Márquez-Malaver, F. J., Alonso, D., Noya, A. M., Carrillo, E., Martino, M. L., Montero, I., González, J., Parody, R., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.09.013 · Cited by 19

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688

Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes

Steidl, C., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kuendgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., Aul, C., et al. (2007) · Clinical Leukemia · doi:10.3816/clk.2007.n.029 · Cited by 8

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A. A. N., Aul, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3978 · Cited by 159